You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
Express Scripts
Baxter
Moodys

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Panitumumab - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for panitumumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Stanford UniversityPhase 1/Phase 2
Tesaro, Inc.Phase 2
Emory UniversityPhase 2

See all panitumumab clinical trials

Recent Litigation for panitumumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD.2019-04-30
Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.2013-10-08
PIECZENIK v. BAYER CORPORATION2010-05-04

See all panitumumab litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-03-20
2018-01-08

See all panitumumab litigation

Pharmacology for panitumumab
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for panitumumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Amgen Fremont Inc. (Fremont, CA) 2017-05-05 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for panitumumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for panitumumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0335 Netherlands   Start Trial 300335, 20180505, EXPIRES: 20221202
C/GB08/009 United Kingdom   Start Trial PRODUCT NAME: PANITUMUMAB; REGISTERED: UK EU/1/07/423/001 20071205; UK EU/1/07/423/002 20071205; UK EU/1/07/423/003 20071205
2008001 Lithuania   Start Trial PRODUCT NAME: PANITUMUMABUM; REGISTRATION NO/DATE: ANUM>EU/1/07/423/001-003 20071203
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.